Saxagliptin News and Research

RSS
Oral regimens could offer simple solution for severe hyperglycaemia

Oral regimens could offer simple solution for severe hyperglycaemia

New edition of RADAR includes review of glycopyrronium for COPD treatment

New edition of RADAR includes review of glycopyrronium for COPD treatment

Bristol-Myers Squibb signs agreement to sell global diabetes business

Bristol-Myers Squibb signs agreement to sell global diabetes business

DPP-4 inhibitors may reduce risk of autoimmune diseases

DPP-4 inhibitors may reduce risk of autoimmune diseases

Short-term blood sugar control in diabetes patients has limited effect on risk of cardiovascular problems

Short-term blood sugar control in diabetes patients has limited effect on risk of cardiovascular problems

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

EU approves Forxiga for treatment of type 2 diabetes

EU approves Forxiga for treatment of type 2 diabetes

Bristol-Myers Squibb completes acquisition of Amylin

Bristol-Myers Squibb completes acquisition of Amylin

Bristol-Myers Squibb to acquire Amylin

Bristol-Myers Squibb to acquire Amylin

European Commission approves ONGLYZA as combination therapy with insulin for type 2 diabetes

European Commission approves ONGLYZA as combination therapy with insulin for type 2 diabetes

ONGLYZA used with insulin maintains improvement in glucose control in adults with type 2 diabetes

ONGLYZA used with insulin maintains improvement in glucose control in adults with type 2 diabetes

European Commission approves BMY's ONGLYZA to treat type 2 diabetes

European Commission approves BMY's ONGLYZA to treat type 2 diabetes

FDA approves ONGLYZA to treat type 2 diabetes patients with renal impairment

FDA approves ONGLYZA to treat type 2 diabetes patients with renal impairment

New research: Fluid retention may explain drugs' risk of strokes and heart attacks

New research: Fluid retention may explain drugs' risk of strokes and heart attacks

Body weight loss influences prescribing decisions for type 2 diabetes

Body weight loss influences prescribing decisions for type 2 diabetes

FDA approved KOMBIGLYZE XR for type 2 diabetes mellitus now available in pharmacies

FDA approved KOMBIGLYZE XR for type 2 diabetes mellitus now available in pharmacies

Study: ONGLYZA and metformin improve HbA1c levels for adult patients with type 2 diabetes at 76-weeks

Study: ONGLYZA and metformin improve HbA1c levels for adult patients with type 2 diabetes at 76-weeks

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

ONGLYZA-metformin combination: FDA accepts NDA for review

ONGLYZA-metformin combination: FDA accepts NDA for review

Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes

Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes